Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients

American Journal of Cardiology

Volumn 92, Issue 6, 2003, Pages 670-676

  Newman, Connie B ^a   Palmer, Gary ^b   Silbershatz, Halit ^b   Szarek, Michael ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; MYALGIA; MYOPATHY; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SIDE EFFECT; SKIN APPENDAGE DISEASE; SKIN DISEASE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UROGENITAL TRACT DISEASE;

EID: 0041526376     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00820-8     Document Type: Article

References (30)

1. Food and Drug Administration. Baycol talk paper. Available at http://www. fda.gov/bbs/topics/ANSWERS/2001/ANS01095;html. Accessed May 14, 2003.
2. Pearson T.A., Laurora I., Chu H., Kafonek S. The Lipid Treatment Assessment Project (L-TAP) a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals . Arch Intern Med. 160:2000;459-467.
3. EUROASPIRE. A European Society of cardiology survey of secondary prevention of coronary disease principal results . Eur Heart J. 18:1997;1569-1582.
4. The clinical reality of coronary prevention guidelines. A comparison of EUROSPIRE I and II surveys in nine countries. Lancet. 357:2001;995-1001.
5. COSTART. Coding Symbols for Thesaurus of Adverse Reaction Terms. 4th Ed. Washington, DC: Food and Drug Administration, Department of Health and Human Services, 1993.
6. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA. 285:2001;1711-1718.
7. Pitt B., Waters D., Brown W.V., Van Boven A.J., Schwartz L., Title L.M. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med. 341:1999;70-76.
8. Pasternak R.C., Smith S.C. Jr, Bairey-Merz C.N., Grundy S.M., Cleeman J.I., Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 40:2002;568-573.
9. Bakker-Arkema R.G., Nawrocki J.W., Black D.M. Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. Atherosclerosis. 149:2000;123-129.
10. Endo A., Tsujita Y., Kuroda M., Tanzawa K. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur J Biochem. 77:1977;31-36.
11. Ma P.T., Gil G., Sudhof T.C., Bilheimer D.W., Goldstein J.L., Brown M.S. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA. 83:1986;8370-8374.
12. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
13. Bradford R.H., Shear C.L., Chremos A.N., Dujovne C., Downton M., Franklin F.A., Gould A.L., Hesney M., Higgins J., Hurley D.P., et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 151:1991;43-49.
14. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 333:1995;1301-1307.
15. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
16. Pfizer Inc. Lipitor United States Product Insert. Available at: http://www. pfizer.com/hml/pi's/lipitorpi.pdf. Accessed May 14, 2003.
17. Maron D.J., Fazio S., Linton M.F. Current perspectives on statins. Circulation. 101:2000;207-213.
18. Thompson P.D., Clarkson P., Karas R.H. Statin-associated myopathy. JAMA. 289:2003;1681-1690.
19. Farmer J.A. Learning from the cerivastatin experience. Lancet. 358:2001;1383-1385.
20. Benghozi R., Bortolini M., Jia Y., Isaacsohn J.L., Troendle A.J., Gonasun L. Frequency of creatine kinase elevation during treatment with fluvastatin. Am J Cardiol. 89:2002;231-233.
21. Sever P.S., Dahlöf B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) a multicenter randomized controlled trial . Lancet. 361:2003;1149-1158.
22. Nawrocki J.W., Weiss S.R., Davidson M.H., Sprecher D.L., Schwartz S.L., Lupien P.J., Jones P.H., Haber H.E., Black D.M. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 15:1995;678-682.
23. Bertolini S., Bittolo Bon G., Campbell L.M., Farnier M., Langan J., Mahla G., Pauciullo P., Sirtori C., Egros F., Fayyad R., Nawrocki J.W. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis. 130:1997;191-197.
24. Dart A., Jerums G., Nicholson G., d'Emden M., Hamilton-Craig I., Tallis G., Best J., West M., Sullivan D., Bracs P., Black D. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol. 80:1997;39-44.
25. Davidson M., McKenney J., Stein E., Schrott H., Bakker-Arkema R., Fayyad R., Black D. Comparison of the one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol. 79:1997;1475-1481.
26. Hunninghake D., Bakker-Arkema R.G., Wigand J.P., Drehobl M., Schrott H., Early J.L., Abdallah P., McBride S., Black D.M. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract. 47:1998;349-356.
27. Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The CURVES study). Am J Cardiol. 81:1998;582-587.
28. Karalis D.G., Ross A.M., Vacari R.M., Zarren H., Scott R. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol. 89:2002;667-671.
29. Andrews T.C., Ballantyne C.M., Hsia J.A., Kramer J.H. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med. 111:2001;185-191.
30. Insull W., Kafonek S., Goldner D., Zieve F. Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at six weeks. Am J Cardiol. 87:2001;554-559.